Entry and competition in generic biologics

Managerial and Decision Economics

Volumn 28, Issue 4-5, 2007, Pages 439-451

  Grabowski, Henry G ^a,b   Ridley, David B ^a   Schulman, Kevin A ^a  

^a DUKE UNIVERSITY   (United States)

^b Box 90097 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548301970     PISSN: 01436570     EISSN: 10991468     Source Type: Journal    
DOI: 10.1002/mde.1352     Document Type: Article

References (26)

1. Abboud L. 2005. One start-up's path to making biotech clones. Wall Street Journal, August 16, 2005; B1. Available at: http://online.wsj.com/ article/0, SB112414810785913821,00.html. Accessed August 16, 2005.
2. Alonso-Zaldivar R. 2005. For generic pharmaceuticals, the price is right in U.S. Los Angeles Times, August 9, 2005. Available at: http://www.latimes.com/news/nationworld/nation/la-na-pharmaceuticals9_aug09,1, 3367959.story. Accessed August 16, 2005.
3. Bhattacharya J, Vogt WB. 2003. A simple model of pharmaceutical price dynamics. Journal of Law and Economics 46: 599-626.
4. Big Generic Pharma, 2005. The Economist, July 28, 2005. Available at: http://www.economist.com/research/articlesBySubject/PrinterFriendly.cfm? Story_ID = 4233872&subjectID = 531766. Accessed August 16, 2005.
5. Bio Generix Presentation. 2005. Follow-on Biologics Forum: The Delivery of Regulatory, Legal and Business Strategies Balanced by Scientific Debates-Washington, DC, April 27-29, 2005.
6. Bresnahan T. 1989. Empirical studies of industries with market power. In Handbook of Industrial Organization, Vol. 2, Schmalensee R, Willig RD (eds). Elsevier Ltd: Oxford, UK; 1011-1057.
7. Bresnahan T, Reiss P. 1991. Entry and competition in concentrated markets. Journal of Political Economy 91: 977-109.
8. Caves RE, Whinston MD, Hurwicz MA. 1991. Patent expiration, entry, and competition in the U.S. pharmaceutical industry. Brookings Papers on Economic Activity: Microeconomics; 1-66.
9. Chamberlin EH. 1933. The Theory of Monopolistic Competition. Harvard University Press: Cambridge.
10. DiMasi JA, Hansen RW, Grabowski HG. 2003. The price of innovation: new estimates of pharmaceutical development costs. Journal of Health Economics 22: 151-185.
11. Frank R, Salkever D. 1997. Generic entry and the pricing of pharmaceuticals. Journal of Economics and Management Strategy 6: 75-90.
12. Frost & Sullivan. 2003. Biopharmaceutical Industry Analysis - Quantification of Supply and Demand of Manufacturing Analysis, November 2003.
13. Frost & Sullivan. 2005. Strategic Analysis of the World Biogenerics Markets. B613-52 http://www.frost.com/prod/servlet/report-homepage.pag?repid = B613-01-00-00-00.
14. Grabowski H, Vernon J. 1992. Brand loyalty, entry and price competition in pharmaceuticals after the 1984 Pharmaceutical Act. Journal of Law and Economics 35: 331-350.
15. Grabowski H, Vernon J. 1996. Longer patents for increased generic competition in the US: the Waxman-Hatch Act after one decade. Pharmacoeconomics 10(Suppl): 110-123.
16. Humphreys A. 2004. Difficult path for biogenerics, MedAdNews, December 2004.
17. Lu ZJ, Comanor W. 1998. Strategic pricing of new pharmaceuticals. Review of Economics and Statistics 80: 108-118.
18. Mathews AW. 2005. Suit presses generic-biotech issue. Wall Street Journal, September 14, 2005; D4.
19. Molowa DT. 2001. The state of biologies manufacturing, J.P. Morgan Securities Inc. Equity Research Healthcare Research Note. February 16, 2001.
20. Polastro ET, Little AD. 2001. The future of biogenerics. Contract Pharma Web site. Available at: http://www.contractpharma.com/archive/2001/10/feature2. php. Accessed August 16, 2005.
21. Reiffen D, Ward MR. 2005. Generic pharmaceutical industry dynamics. Review of Economics and Statistics 87: 37-49.
22. Reiffen D, Ward MR. 2007. 'Branded generics' as a strategy to limit cannibalization of pharmaceutical markets. Managerial and Decision Economics 28: 251-265.
23. Saha A, Grabowski HG, Birnbaum H, Greenberg P, Bizan O. 2006. Generic competition in the U.S. pharmaceutical industry. International Journal of the Economics of Business 13: 15-38.
24. Scott Morton F. 1996. Entry decisions in the generic pharmaceutical industry. RAND Journal of Economics 30: 421-440.
25. Skinner BJ. 2005. Seniors and pharmaceutical prices in Canada and the United States. Fraser Institute Digital Publication. Available at: http://www.fraserinstitute.ca/admin/books/files/Seniors& PharmaceuticalPrices CanUS.pdf. Accessed August 16, 2005.
26. Wiggins SN, Maness R. 2004. Price competition in pharmaceuticals: the case of anti-infectives. Economic Inquiry 42: 247-263.